This inventor holds 1 USPTO granted patent. Top assignee: Osi Pharmaceuticals, Inc.. Active years: 1999.
Company Filing History:
Years Active: 1999
Title: Innovations of Nicholas Rich in Erythropoietin Modulation
Introduction
Nicholas Rich is an accomplished inventor based in Birmingham, GB. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that enhance the biosynthesis of erythropoietin. His innovative work has the potential to impact medical treatments and therapies.
Latest Patents
Nicholas Rich holds a patent for "Tetracyclic compounds for enhancing biosynthesis of erythropoietin." This invention provides a compound in substantially pure form with a specific structure that includes various functional groups. The patent outlines the conditions under which these compounds can effectively modulate cellular expression of the mammalian gene encoding erythropoietin, along with a suitable carrier.
Career Highlights
Nicholas Rich is associated with Osi Pharmaceuticals, Inc., where he has been instrumental in advancing research and development in pharmaceutical innovations. His work focuses on creating compounds that can lead to significant advancements in medical science.
Collaborations
Nicholas has collaborated with notable colleagues, including Jonathan G Williams and David R Houck. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Nicholas Rich's contributions to the field of erythropoietin modulation through his patented compounds demonstrate his commitment to advancing medical science. His work continues to pave the way for future innovations in biochemistry and pharmaceuticals.